CMC Regulatory Compliance for Biopharmaceuticals - Updated Guide

In this review of CMC Regulatory Compliance for Biopharmaceuticals the author John Geigert offers a focused resource for regulatory, QA/QC and manufacturing professionals. The book's single biggest reason to buy is its practical examination of how quality assurance and quality control must evolve across development stages to meet a growing body of guidances; readers seeking a grounded, regulatory-focused perspective will find the update especially useful. This review highlights where the book helps operational teams, what it covers about recent guidances, and who will benefit most from its strategic framing.

Key Features

• Coverage of QA/QC roles: Explains the strategic importance of QA/QC involvement in manufacturing control so teams can align quality systems with regulatory expectations.
• Graded approach guidance: Outlines a graded approach from early clinical trials through market approval to help prioritize activities and controls by development stage.
• Regulatory update summary: Summarizes the impact of more than 50 new FDA, EMA and ICH guidances issued since 2004, giving readers context for current compliance demands.
• Biosimilars context: Describes the emergence and regulatory development of biosimilars in Europe and the USA to inform strategy and comparability planning.
• Practical focus: Emphasizes value generated by QA/QC in manufacturing control so professionals can justify and design quality interventions.

Who It's For

This book is best for quality assurance and quality control managers, regulatory affairs professionals, and manufacturing leaders working in biopharmaceutical development who need a concise review of contemporary CMC expectations. It is particularly helpful for those building or revising quality strategies to address a rapidly changing guidance landscape.

Those looking for laboratory protocols, step-by-step analytical methods, or highly technical chemical process details should look elsewhere; the book is framed around regulatory strategy and quality oversight rather than bench procedures or synthetic chemistry techniques.

Pros & Cons

Pros

• Provides a clear strategic case for early and graded QA/QC involvement, useful for organizational planning.
• Collects the effects of many recent guidances into one narrative, saving readers time in catching up on regulatory change.
• Places biosimilars development in regulatory context, aiding comparative planning for product developers.

Cons

• Not a laboratory manual; readers seeking technical assay instructions will find the scope deliberately managerial and strategic.

Specifications

Title	CMC Regulatory Compliance for Biopharmaceuticals
Author	John Geigert
Subject	Quality assurance, quality control, regulatory strategy
Regulatory scope	FDA, EMA and ICH guidances (50+ since 2004)
Audience	QA/QC, regulatory affairs, manufacturing professionals
Focus	Graded QA/QC approach from trials to approval

Our Verdict

John Geigert's updated guide is a practical, strategically minded resource for quality and regulatory professionals in biopharmaceuticals. It is good value for teams that must interpret a growing set of guidances and design a graded QA/QC approach across development stages, though it is not intended as a technical lab reference.

Frequently Asked Questions

Does this book cover recent regulatory guidances?
Yes. The update includes discussion of more than 50 new FDA, EMA and ICH guidances affecting CMC compliance since the first edition.

Is this useful for biosimilars development?
Yes. The book broadens coverage to include the development and regulatory application of biosimilars in Europe and evolving practice in the USA.

Will I find laboratory methods in this book?
No. The focus is on regulatory strategy and QA/QC involvement rather than bench-level protocols or analytical procedures.